2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Primary Myelofibrosis
41
Myeloproliferative Disorders
30
Polycythemia Vera
28
Leukemia, Myeloid, Acute
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Leukemia
17
Myelodysplastic Syndromes
15
Thrombocythemia, Essential
12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Neoplasms
9
Multiple Myeloma
9
Graft vs Host Disease
9
Breast Neoplasms
9
Pancreatic Neoplasms
8
Leukemia, Myelomonocytic, Chronic
8
Recurrence
7
Myelodysplastic-Myeloproliferative Diseases
7
Lymphoma, Non-Hodgkin
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Hematologic Neoplasms
6
Prostatic Neoplasms
5
Lymphoma, T-Cell
5
Lymphoma
5
Leukemia, Myeloid, Chronic-Phase
5
Hodgkin Disease
5
Hematologic Diseases
5
Colorectal Neoplasms
5
Thrombocytosis
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Carcinoma, Non-Small-Cell Lung
4
Interventions
Gels
2
Fulvestrant
2
Doxycycline
2
Dapsone
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
Interviews as Topic
1
IFL protocol
1
Hydrocortisone
1
HIV Testing
1
Fibroblast Growth Factor 7
1
Erlotinib Hydrochloride
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Exanthema
×
ruxolitinib
×
Clear all
NCT06399029
2026-04-30
TRUX-LST
University of Zurich
Phase 2
Active not recruiting
22 enrolled